Novo Nordisk A/S (NVO)
50.29
+1.24
(+2.53%)
USD |
NYSE |
Dec 11, 16:00
50.00
-0.29
(-0.58%)
Pre-Market: 05:32
Novo Nordisk Cash from Investing (Quarterly): -2.440B for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Evaxion AS | -- |
| Ascendis Pharma A/S | -0.2594M |
| Regeneron Pharmaceuticals, Inc. | -402.90M |
| Omeros Corp. | -6.861M |
| Viking Therapeutics, Inc. | 160.02M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 7.308B |
| Cash from Financing (Quarterly) | -2.797B |
| Free Cash Flow | 9.245B |
| Free Cash Flow Per Share (Quarterly) | 1.083 |
| Free Cash Flow to Equity (Quarterly) | 4.503B |
| Free Cash Flow to Firm (Quarterly) | 4.817B |
| Free Cash Flow Yield | 4.13% |